Published in J Clin Microbiol on July 01, 1988
Evaluation of enzyme immunoassays for detection of delta antigen and antibody. J Clin Microbiol (1989) 1.22
Immune response to synthetic peptides of hepatitis delta antigen. J Clin Microbiol (1993) 1.16
Evaluation of five hepatitis delta virus marker assays for detection of antigen and antibody. J Clin Microbiol (1989) 0.96
Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies. J Clin Microbiol (1991) 0.92
Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging. J Clin Microbiol (2015) 0.83
New enzyme-linked immunosorbent assay for detection of antibodies against hepatitis delta virus using a hepatitis delta antigen derived from a Taiwanese clone and comparison to the Abbott radioimmunoassay. Clin Vaccine Immunol (2012) 0.83
Comparison of Enzyme Immunoassays for Detection of Antibodies to Hepatitis D Virus in Serum. Clin Vaccine Immunol (2016) 0.78
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol (1980) 2.57
Infection with delta agent in Sweden: introduction of a new hepatitis agent. J Infect Dis (1982) 1.55
Serological response to the hepatitis delta virus in hepatitis D. Lancet (1987) 1.50
Infection with the delta agent in chronic HBsAg carriers. Gastroenterology (1981) 1.48
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (delta) antigen:" clinical significance in delta infection. J Med Virol (1982) 1.38
Sensitive enzyme immunoassay for the detection of delta antigen and anti-delta, using serum as the delta antigen source. J Med Virol (1984) 1.30
Delta hepatitis in inapparent carriers of hepatitis B surface antigen. A disease simulating acute hepatitis B progressive to chronicity. Gastroenterology (1983) 0.98
Delta agent infection in acute hepatitis and chronic HBsAg carriers with and without liver disease. Gut (1984) 0.95
Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses. Gastroenterology (1983) 0.92
Detection of IgM antibodies to delta antigen after coinfection and superinfection with the delta virus. J Med Virol (1986) 0.89
[21st meeting of the French Association for the Study of the Liver. Paris, France, 28 November 1986. Abstracts]. Gastroenterol Clin Biol (1987) 0.88
Serological diagnosis of acute delta hepatitis. J Med Virol (1986) 0.87
Identification of a high-virulence clone of type III Streptococcus agalactiae (group B Streptococcus) causing invasive neonatal disease. Proc Natl Acad Sci U S A (1989) 3.66
Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet (1981) 2.31
Characterization of Streptococcus agalactiae strains by multilocus enzyme genotype and serotype: identification of multiple virulent clone families that cause invasive neonatal disease. J Clin Microbiol (1995) 2.13
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Relapse of herpes simplex encephalitis. J Child Neurol (1995) 1.66
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Urogenital, maternal and neonatal isolates of Haemophilus influenzae: identification of unusually virulent serologically non-typable clone families and evidence for a new Haemophilus species. J Gen Microbiol (1990) 1.59
Hepatitis delta virus infection in French male HBsAg-positive homosexuals. Hepatology (1989) 1.51
Genetic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis revealed by restriction fragment length polymorphism of the rRNA gene region. J Clin Microbiol (1995) 1.46
Cross-sectional and longitudinal epidemiology of hepatitis B in Senegal. Prog Med Virol (1981) 1.45
Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses (1996) 1.42
Genetic characterization of a cryptic genospecies of Haemophilus causing urogenital and neonatal infections. J Clin Microbiol (1993) 1.41
CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. Am J Transplant (2013) 1.40
Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle. Virology (1997) 1.36
Prevalence of human T-lymphotropic retroviruses type III (HIV) and type IV in Ivory Coast. Lancet (1987) 1.35
Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis (1986) 1.35
Immunisation against hepatitis B in man. Lancet (1976) 1.31
Typing of urogenital, maternal, and neonatal isolates of Haemophilus influenzae and Haemophilus parainfluenzae in correlation with clinical source of isolation and evidence for a genital specificity of H. influenzae biotype IV. J Clin Microbiol (1989) 1.29
Thymic abnormalities in fetuses aborted from human immunodeficiency virus type 1 seropositive women. Pediatrics (1992) 1.28
Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch Virol (1998) 1.28
Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology (1997) 1.24
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol (2007) 1.22
Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol (2000) 1.20
Human immunodeficiency virus antigenemia in patients with AIDS and AIDS-related disorders: a comparison between European and Central African populations. J Infect Dis (1987) 1.17
Hepatitis B virus DNA in primary hepatocellular carcinoma tissue. J Med Virol (1978) 1.17
Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping. J Clin Microbiol (1998) 1.17
False positive result of Mycobacterium tuberculosis complex DNA probe hybridization with a Mycobacterium terrae isolate. Eur J Clin Microbiol Infect Dis (1993) 1.16
Immune response to synthetic peptides of hepatitis delta antigen. J Clin Microbiol (1993) 1.16
Frequent and early in utero HIV-1 infection. AIDS Res Hum Retroviruses (1991) 1.13
Active immunization against hepatitis B in an area of high endemicity. Part I: Field design. Prog Med Virol (1981) 1.12
Immune response in neonates to hepatitis B vaccine. Lancet (1982) 1.11
[Hepatitis B virus and primary liver carcinoma: evidences for a filiation hepatitis B, cirrhosis and primary liver cancer]. Ann Microbiol (Paris) (1977) 1.10
In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates. Antimicrob Agents Chemother (1988) 1.09
Direct appraisal of latex agglutination testing, a convenient alternative to enzyme immunoassay for the detection of rotavirus in childhood gastroenteritis, by comparison of two enzyme immunoassays and two latex tests. J Clin Microbiol (1985) 1.08
Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol (1998) 1.03
Hepatitis-B vaccination in the elderly. J Infect Dis (1984) 1.03
Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis (1985) 1.02
The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs. J Infect Dis (1998) 1.00
Adherence to human cells of a cryptic Haemophilus genospecies responsible for genital and neonatal infections. Infect Immun (1993) 1.00
Evaluation of four commercial methods for identification and biotyping of genital and neonatal strains of Haemophilus species. Eur J Clin Microbiol Infect Dis (1992) 0.99
[Maternal-fetal Haemophilus influenzae infections]. Presse Med (1987) 0.99
Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations. J Clin Microbiol (1993) 0.99
Hepatitis B, C, D, and E markers in rural equatorial African villages (Gabon). Am J Trop Med Hyg (1995) 0.99
Early asymptomatic hepatitis A in Senegalese children. Lancet (1980) 0.97
Lack of anti-HBc IgM in neonates with HBsAg carrier mothers argues against transplacental transmission of hepatitis B virus infection. Lancet (1983) 0.95
Characterization of RNA-binding domains of hepatitis delta antigen. J Gen Virol (1993) 0.94
Hepatitis B core antigen in hepatocytes of patients with chronic active hepatitis. Dig Dis Sci (1980) 0.93
Frequent isolation of capnophilic bacteria in aspirate from Bartholin's gland abscesses and cysts. Eur J Clin Microbiol Infect Dis (1990) 0.92
Automated complement fixation test for the detection of antibodies against the core of hepatitis B virus (HBc). J Immunol Methods (1976) 0.89
Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2. J Virol (1990) 0.89
Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV-2/simian immunodeficiency virus. J Clin Microbiol (1991) 0.89
[Seroepidemiology of hepatitis A in six departments in West-Central France in 1991]. Gastroenterol Clin Biol (1992) 0.88
[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin]. Pathol Biol (Paris) (2004) 0.88
Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection. J Acquir Immune Defic Syndr (1993) 0.86
Hepatitis B vaccine: immunization of children and newborns in an endemic area (Senegal). Dev Biol Stand (1983) 0.86
Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection. J Med Virol (1997) 0.86
Non-A, non-B fulminant viral hepatitis in France in returnees from Asia and Africa. Dig Dis Sci (1987) 0.86
Prevention of hepatitis B virus infection in children born to HBsAg positive/HBeAg positive mothers. Preliminary results of active and passive-active immunization. Dev Biol Stand (1983) 0.85
Use of nonradioactive DNA probes to identify a Campylobacter jejuni strain causing abortion. Eur J Clin Microbiol Infect Dis (1993) 0.85
Detection of avian oncogenic Marek's disease herpesvirus DNA in human sera. J Gen Virol (2001) 0.85
Multiplication of hepatitis B virus in fulminant hepatitis B. Br Med J (Clin Res Ed) (1984) 0.85
Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection. J Med Virol (1992) 0.84
Hepatitis B infection in alcoholic liver disease and primary hepatocellular carcinoma in France. Prog Med Virol (1981) 0.84
Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci (1988) 0.84
Hepatitis B virus core antigen (HBc Ag) accumulation in an HBV nonproducer clone of HepG2-transfected cells is associated with cytopathic effect. Virology (1990) 0.83
Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975-September 1982). Dev Biol Stand (1983) 0.83
Immunogenicity of low dose (1.25 and 0.31 micrograms) hepatitis B vaccine. Lancet (1984) 0.83
Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology (1978) 0.82
Immunogenicity in chimpanzees of experimental hepatitis B vaccines prepared from intact hepatitis B virus, purified polypeptides, or polypeptide micelles. J Med Virol (1982) 0.82
Interaction between hepatitis delta virus-encoded proteins and hepatitis B virus envelope protein domains. J Gen Virol (1998) 0.82
Immune response to a major epitope of p24 during infection with human immunodeficiency virus type 1 and implications for diagnosis and prognosis. J Clin Microbiol (1991) 0.82
[Systematic screening tests for Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in urogenital specimens of infertile couples]. Pathol Biol (Paris) (2005) 0.82
[Thyroid function and autoimmunity in 215 patients seropositive for the hepatitis C virus]. Ann Endocrinol (Paris) (1998) 0.81
Combined passive and active immunization for interruption of perinatal transmission of hepatitis B virus in Taiwan. Hepatogastroenterology (1985) 0.81
Epidemiology of primary hepatocellular carcinoma in Senegal. Prog Med Virol (1981) 0.81
Large scale purification of hepatitis B surface antigen (HBsAg). Ann Microbiol (Paris) (1978) 0.80
Serum alanine aminotransferase measurement as a guide to selective testing for hepatitis C during medical checkup. J Hepatol (1994) 0.80
Antibody to hepatitis B core antigen in chronic active hepatitis. Br Med J (1978) 0.79
Influence of human immunodeficiency virus infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat (1994) 0.79
[Evaluation of a new latex test for detecting human rotaviruses in feces]. Pathol Biol (Paris) (1985) 0.79
[Pediatric osteoarticular infections caused by Kingella kingae from 1995 to 2006 at CHRU de Tours]. Ann Biol Clin (Paris) (2008) 0.79
High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. AIDS Res Hum Retroviruses (1993) 0.79
Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia. Infect Immun (1983) 0.79
[Should hepatitis C be screened? Analysis of oriented screening strategies for hepatitis C virus infection]. Gastroenterol Clin Biol (1997) 0.79
Epidemiological and serological study of hepatitis A virus outbreaks in France: a comparison between immunoadherence and radioimmunoassay. J Hyg (Lond) (1981) 0.79
Competitive enzyme-immunoassays using native viral antigens to discriminate between HIV-1 and HIV-2 infections. J Virol Methods (1990) 0.79
Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine (1991) 0.78
Vaccine against hepatitis B--18 months prevention in a high risk setting. Med Microbiol Immunol (1978) 0.78
Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? J Viral Hepat (2007) 0.78
[Transmission by colonoscopy of hepatitis C virus: apropos of a group of 97 patients at "presumed risk"]. Gastroenterol Clin Biol (1999) 0.78
[Sero-epidemiological study of hepatitis A infection in Senegalese children (author's transl)]. Ann Pediatr (Paris) (1980) 0.78
[Varicella and primary achalasia of the lower esophageal sphincter]. Gastroenterol Clin Biol (1996) 0.78
Active immunization against hepatitis B in an area of high endemicity. Part II: Prevention of early infection of the child. Prog Med Virol (1981) 0.78
Isolation of hepatitis B surface antigen (HBsAg) by affinity chromatography on antibody-coated immunoadsorbents. J Immunol Methods (1975) 0.78
Further studies on production and characterization of HBsAg derived from a human hepatoma cell line (PLC/PRF/5). Dev Biol Stand (1983) 0.78
Symptomatic HIV-2 primary infection. Lancet (1990) 0.78
Letter: Cross-reaction of human serum-proteins with HBsAg. Lancet (1974) 0.78
[The identification of hepatitis A virus in faeces. Diagnosis and epidemiological value (author's transl)]. Nouv Presse Med (1977) 0.78
Direct investigation of protein RNA-binding domains using digoxigenin-labelled RNAs and synthetic peptides: application to the hepatitis delta antigen. J Virol Methods (1995) 0.78
[Anti-HCV serology for screening, diagnosis and surveillance of hepatitis C: role of the immunoblot]. Ann Biol Clin (Paris) (1998) 0.77